摘要
目的探讨非小细胞肺癌(NSCLC)患者肿瘤组织内核苷酸切除修复交叉互补基因1(ERCC1)表达与吉西他滨联合顺铂(GP方案)化疗疗效的相关性。方法采用免疫组化S-P法检测51例Ⅱb～Ⅳ期NSCLC患者肿瘤组织内ERCC1的表达。所有患者接受至少2个周期以上的GP方案化疗,对患者化疗后的中位生存期(MST)及化疗后反应率(RR)进行评估。结果 51例患者ERCC1的阳性表达率为43.14%(22/51)。ERCC1表达阳性组化疗后的RR和MST分别为50.0%、17个月,与阴性组RR(31.04%)、MST(12个月)比较,差异无统计学意义(χ2=1.8877,P=0.1695;χ2=1.6767,P=0.1954)。结论 ERCC1表达阳性的NSCLC患者能从吉西他滨联合顺铂的化疗中受益,调控ERCC1表达逆转耐药的策略,将为肿瘤治疗带来新的方法和途径。
Objective To explore the relationship between the expression of excision repair cross-completion 1（ERCC1） and the curative effect of cisplation combined with gemcitabine（GP） chemotherapy in patients with non-small cell Lung Cancer（NSCLC）.Methods The expression of ERCC1 was examined by immuno-histochemical technique in 51 patients with stage Ⅱb-Ⅳ NSCLC.All patients were at least received 2 cycles of cisplation combined with gemcitabine chemotherapy.The median survival time（MST）and the response rate（RR） were evaluated after chemotherapy.Results The expression of ERCC1 was 43.14% among 51 cases.The response rate（RR） and the median survival time（MST） of ERCC1 positive group were 50.0%,17 months.The RR and MST of ERCC1 negative group were 31.04%,12 months.The differences of RR and MST between two groups above were not statistical significance（P=0.1695,P=0.1954）.Conclusion The NSCLC patients with positive expression of ERCC1 get more benefits from cisplation combine gemcitabine chemotherapy.The device that regulate and control the expression of ERCC1 will bring new treatment and way for the tumor.
出处
《中国肿瘤临床与康复》
2011年第5期464-467,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
